Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phentermine-topiramate→

Phentermine-topiramate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
960078-81-3
PubChem CID
9848354
Molecular formula
C22H36N2O8S
Molecular weight
488.6 g/mol
Drug class
Fixed-dose anti-obesity combinationsympathomimetic anorectic plus anticonvulsant
Mechanism of action
Phentermine promotes hypothalamic catecholamine release and suppresses appetite. Topiramate contributes to appetite and satiety effects through multiple mechanisms, including modulation of GABAergic signalling, voltage-gated ion channels, glutamate receptors and carbonic anhydrase.
Indications / reported uses
  • Long-term adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and eligible adolescents with obesity or overweight with weight-related comorbidities, according to the current product label.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf · https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=876bd763-13fa-481e-b579-c2fc44dbf3c2&type=display · FDA product information

Identification source: PubChem record (CID 9848354). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phentermine-topiramate Environmental Risk Assessment (ERA) (the Phentermine-topiramate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.